Telix’s brain cancer program comprises an investigational therapy and an investigational PET imaging agent – both small molecule-based.

Therapy

• TLX101 (¹³¹I-IPA) is Telix’s investigational therapy for GBM, currently being evaluated in front line and recurrent GBM in the IPAX series of studies

TLX102 (²¹¹At-APA) is Telix’s investigational alpha therapy being developed as a potential complement to the TLX101 and TLX101-CDx programs. TLX102 has demonstrated pre-clinical proof-of-concept in glioblastoma and multiple myeloma. In August 2020, TLX102 was granted orphan drug designation from the FDA for the treatment of multiple myeloma.

Imaging

• TLX101-CDx (¹⁸F-floretyrosine or ¹⁸F-FET) is Telix’s PET agent for imaging gliomas, widely used in clinical research settings including in Telix’s IPAX studies as a complementary diagnostic agent to the company’s TLX101 GBM investigational therapy.

TLX101 and TLX101-CDx have been granted orphan drug designation in the United States and Europe.